Print | Need Larger Text?

Incident Report

Subform I: General Information

1. Report Type.

New incident report

Incident Report Number: 2009-3145

2. Registrant Information.

Registrant Reference Number: CER10702

Registrant Name (Full Legal Name no abbreviations): Syngenta Crop Protection

Address: 140 Research Lane, Research Park

City: Guelph

Prov / State: ON

Country: Canada

Postal Code: N1G4Z3

3. Select the appropriate subform(s) for the incident.

Scientific Study

4. Date registrant was first informed of the incident.

5. Location of incident.

6. Date incident was first observed.

Product Description

7. a) Provide the active ingredient and, if available, the registration number and product name (include all tank mixes). If the product is not registered provide a submission number.

PMRA Registration No.       PMRA Submission No.       EPA Registration No.

Product Name:

• Active Ingredient(s)
  • PIRIMICARB

7. b) Type of formulation.

Application Information

8. Product was applied?

Unknown

9. Application Rate.

10. Site pesticide was applied to (select all that apply).

11. Provide any additional information regarding application (how it was applied, amount applied, the size of the area treated etc).

To be determined by Registrant

12. In your opinion, was the product used according to the label instructions?

Unknown

Subform VII: Scientific Study

1. Study Reference

Title Tunnel Test - acute and short term effects of PIRIMOR G and CER 10702, applied on oil seed rape or phacelia, on honey bbes

Date 03-JUN-08

2. a) Is an extension needed to translate the document?

No

3. Type of incident identified in the study

Presence of a component or derivitive

4. Describe the incident identified in the study (e.g. study demonstrates an increased risk to non-Hodgkin's Lymphoma after exposure to pesticide X)

Two acute honey bee studies were conducted in France in wheat. The application rate was 375 g ai/ha = 0.33 lb ai/A = 5.36 oz ai/A. The pirimicarb treatments in these studies generally resulted in higher mortality than observed in previous studies. However, there were some quality issues with these studies, i.e. the untreated control groups also experienced higher mortality than expected.

5. a) Was the study discontinued before completion?

No

5. b) Provide the reason for discontinuation

6. If the study is ongoing, what is the expected completion date?

For Registrant use only

7. Provide supplemental information here